

INFORMATION DISCLOSURE **CITATION**

ATTORNEY'S DKT No. 012712-905

APPLICATION No. Not Assigned

APPLICANT

Nabil HANNA et al.

1					Nabil HANNA et al.					
PTO-1449				FILING DATE July 10, 200	0	GROUP Not Assigned				
		U.\$. PATENT DO	CUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME		CLASS	SUBCLASS	FILING DAT			
	4,816,567	3/28/89	Cabilly et al.		530	387	2	<u>.</u>		
	4,973,745	12/18/90	Schoemake	er et al.	530	387	47			
	4,975,369	12/04/90	Beavers et al.		435	69	25			
	4,816,397	3/28/89	Boss et al.		435	68	264			
							P .			
		FOREIC	GN PATENT I	OCUMENTS		<u> </u>		· · ·		
EXAMINER'S INITIALS	DATENT NO			Assetting to the state of the s			Trans	slation		
	PATENT NO. 9008198	7/26/90	PCT	DUNTRY	CLASS	SUBCLASS	Yes	No		
		7720730	PCI							
	EP 0 523 949 A1	01/20/93	EUROPE							
	EP 0 451 216 B1	10/16/91	EUROPE				<u> </u>			
	EP 0 682 040 A1	11/15/95	EUROPE							
	OTHER DOCUM	ENTS (Includ	ding Author.	Title Date P	ertinent Page	e Etá l				
	Jones, P.T. et al., I	Nature, 321:	522. (1986)	- A - A - A - A - A - A - A - A - A - A	ortine i age	13, ELG./	1/2 - Page 1/2			
	Camerini, D. and Seed, B., Cell, 60:747, (1990)									
	McClure, M.O. et a									
	Truneh, A. et al., Cell. Immun., 131:98, (1990)									
	Nishimura, Y. et al., Cancer Research, 47:999 (1987)									
	Ward, E.S. et al., Nature, 341:544 (1989)									
	Camerini, D. and Se 587, (1989)			P. 125, V Int	ernational Co	onference on	AIDS	, pg.		
	Persson et al., Proc	Natl. Acad.	Sci. USA, 8	B:2432, 1991						
	Meek et al., J. Immun., 146:2434, 1991									
	Allison et al., J. Immunological Methods, 95:157, 1986									
	Ehrlich et al., Hybridoma, Vol. 7, No. 4, pp. 385-395, 1988 Ehrlich et al., Clin. Chem., 34:1681, 1988 Van Meel et al., J. Immunological Methods, 80:267, 1985									
	BS Heteromycloma I			1130., 1300	· · · · · · · · · · · · · · · · · · ·					
	Ehrlich et al., Hum.			90, vol. 1, no	. 1.					
XAMINER				E CONCIDED						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

SHEET 2 OF 3

										
INFORMATION DISCLOSURE CITATION PTO-1449				ATTORNEY'S DKT No. 012712-905		APPLICATION NO. Not Assigned				
				APPLICANT Nabil HANNA et a	al.					
				FILING DATE July 10, 2000		GROUP Not Assigned				
		U:S	. PATENT D	OCUMENTS						
EXAMINER'S				Comments of the second of		FILING	DATE			
INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS		-		
						!				
					1]				
					1					
					 	 				
	<u> </u>	FORE	IGN PATENT	DOCUMENTS -		· .				
EXAMINER'S						0.11001.400	Transl			
INITIALS	PATENT NO.	DATE	c	OUNTRY	CLASS	SUBCLASS	Yes	No		
		İ						<u> </u>		
					Į.	}				
					<u>-</u>					
	OTHER DOG	UMENTS (Inc	luding Autho	or, Title, Date, Per	tinent≀Pa	ges, Etc.)				
	Ehrlich et al., Hybridoma, Vol. 6, No. 2, pp. 151-160, 1987 Herpes Transformation, abstract									
	Amoroso et al., J. Immun., 145:3155, 1990									
	Huse et al., Science, 246:1275, 1989									
	Letvin et al	Effect of Reco	ombinant Sol	luble CD4 in Rhes Abstract from the	us Monke V Int. Co	eys Infected V nf. on AIDS,	Vith Sir 1989, _I	mian p.		
	Rosenberg, M.	or", 2:107, (1	990)	ole recombinant C						
	Riechmann, L.	et al., <u>Natur</u>	e, "Reshapin	g human antibodio						
	Houghton, A.N. et al., <u>Seminars in Oncology</u> , "Monoclonal antibodies potential application to the treatment of cancer", 13:165, (1986). Watanabe, M. et al., Proceedings of the National Academy of Sciences, 88:4616-462									
	(1991).						6-462	o, 		
				OLOGICAL METH	DDS (198	6) 123.				
	Morrison Scie			(5)						
	Immunology T									
	Queen et al.,					-				
	Waldmann Sc									
	Hied et al., G	enes and can	cer (1990) p							
EXAMINER	l .			DATE CONSIDER	KED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORM	ATION DISCI	OSURE CI	ATTORNEY'S DKT NO. 012712-905		APPLICATION NO. Not Assigned				
INFORMATION DISCLOSURE CITATION PTO-1449				APPLICANT Nabil HANNA et al.					
						GROUP Not Assigned			
		U.	S. PATENT D	OCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS	FILING	DATE	
	-	-							
		FOR	EIGN PATENT	DOCUMENTS	<u> </u>		L		
EXAMINER'S				New Assessment :		011001400	Transl		
INITIALS	PATENT NO.	DATE	C(OUNTRY	CLASS	SUBCLASS	Yes	No	
									
					ļ				
	OTHER DOC	L UMENTS:(Iñ:	l cludina∦Autho	r, Title, Date, Per	_l tinent⊦Pag	jes, Etc.)	(*)		
	 6. 15 St. 18 SUGSE DAMAS. 7 	2" to 1" 1 \$ 20 20 00 00 00 00 00 00 00 00 00 00 00	2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	ed October 1985,	A. C. C. S. C.		key B	19	
	lymphocyte su cultures", page	bpopulations es 549-553.	transformed	by baboon herpes	virus in v	vivo and in ti	ssue		
	Harris et al., T.								
	Truneh et al., ' Antibody Reac November 199	tivity Restric	ted to Xeno-H	nomolgus Macaqu Iuman Determinar 98-108.	es to Hun nts" CELL	nan Soluble (ULAR IMMUI	CD4: NOLOG	Υ,	
	Van Meurs et a	al. "Production	on of Primate	Monoclonal Antib I. 95, pp. 123-12		OURNAL OF			
	Schroeder et al. "Early Restriction of the Human Antibody Repertoire" SCIENCE, 6, 1987, Vol. 238, Pages 791-793.								
	Immunoglobuli Deletion Mech 1513-1522.	n Lambda Lig anism" EURC	ght Chain Loc OPEAN JOURN	da-C Lambda Gen us are Separated NAL OF IMMUNOL	by 14 KB LOGY, Ju	and Rearran ne 1991, Vol	ge by a l. 21, P	ages	
·	VL Domains of RH-Blood Grou Pages 135-140	f Two Humai ip System" T 0.	n Monoclonal THE BIOCHEM	ces and Three-Dir Antibodies Specif ICAL JOURNAL, I	ic for the May 15, 1	D Antigen o	f the H 68, No.	umar 1,	
	Glycoprotein o	of Human Imr Dons Immuni	munodeficiend zed with a Ca	ed to the Variable by Virus Type 1 in ndidate Recombir 23, No. 5, Pages 1	Chimpan ant Vacc	zees Infected ine" THE JOI	d with 1	the	
EXAMINER	DATE CONSIDERED								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.